GlassScriptPhysician profile
David C Levi
NPI 1518955236
$4,844.62
in general payments reported to CMS, 2019-2025
30 companies · $293 in 2025
The $293 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,112 · 2020: $495 · 2021: $633 · 2022: $689 · 2023: $928 · 2024: $695 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,762 · Education: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,762.38 |
| Education | $153.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,645.52 | 2019-2025 | Wavewriter Alpha Prime 16 |
| Collegium Pharmaceutical, INC. | $419.35 | 2019-2024 | Xtampza |
| Scilex Pharmaceuticals INC. | $417.51 | 2019-2021 | |
| Abbvie INC. | $376.11 | 2021-2024 | |
| Medtronic USA, INC. | $255.93 | 2019 | |
| Medtronic, INC. | $248.65 | 2021-2025 | Intellis Adaptivestim, Inceptiv |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $240.71 | 2019-2023 | Relistor |
| Abbott Laboratories | $210.51 | 2019-2022 | |
| Ortho Systems | $153.01 | 2024 | |
| Horizon Therapeutics Plc | $88.52 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $83.37 | 2019-2021 | |
| Daiichi Sankyo INC. | $72.60 | 2019 | |
| Grt US Holding, INC. | $68.76 | 2020-2022 | |
| Almatica Pharma LLC | $62.14 | 2021-2022 | |
| Nevro Corp. | $59.61 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zyla Life Sciences, INC. | $59.13 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $46.41 | 2021-2023 | Kristalose |
| Astrazeneca Pharmaceuticals LP | $42.96 | 2019 | |
| Kaleo, INC. | $38.07 | 2019 | |
| Pfizer INC. | $36.43 | 2021 | |
| Vertical Pharmaceuticals, LLC | $35.00 | 2019 | |
| Lilly USA, LLC | $27.31 | 2021 | |
| Nalu Medical, INC. | $26.50 | 2022 | |
| Vertos Medical, INC. | $23.70 | 2024 | Mild Device Kit |
| Novartis Pharmaceuticals Corporation | $21.84 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $21.22 | 2022 | |
| Fidia Pharma USA INC. | $16.14 | 2019 | |
| Biodelivery Sciences International, INC. | $16.09 | 2020 | |
| Stryker Corporation | $15.93 | 2019 | |
| Idorsia Pharmaceuticals US INC | $15.59 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Levi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.